Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multi-centric, Comparative, Randomized, Parallel group, double-blind, placebo-controlled, phase III clinical trial study to evaluate safety and efficacy of the drug products ReliBeta (Reliance Life Sciences Pvt. Ltd.,India) versus Avonex (Biogen Idec Limited, Great Britain) in the treatment of patients with remitting multiple sclerosis and open after-treatment with Interferon β1а - REAV

Trial Profile

An International, Multi-centric, Comparative, Randomized, Parallel group, double-blind, placebo-controlled, phase III clinical trial study to evaluate safety and efficacy of the drug products ReliBeta (Reliance Life Sciences Pvt. Ltd.,India) versus Avonex (Biogen Idec Limited, Great Britain) in the treatment of patients with remitting multiple sclerosis and open after-treatment with Interferon β1а - REAV

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors RCI Syntez
  • Most Recent Events

    • 02 Sep 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top